Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TECOS: Sitagliptin Cardiovascular Outcomes in Type 2 Diabetes
NCT00790205Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2008
- Primary completion
- Mar 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin with Placebo (2 arms). Primary endpoint: Major Adverse Cardiovascular Event Plus up to 5 years. Started Dec 2008; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00790205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00790205.